厄贝沙坦氢氯噻嗪对高血压患者血压变异性和左心室肥厚的影响  

Effects of irbesartan and hydrochlorothiazide on blood pressure variability and left ventricular hypertrophy in patients with hypertension

作　　者：李久峰 LI Jiu-feng(Huakang Hospital of Tiexi District,Shenyang 110026,China)

机构地区：[1]辽宁省沈阳市铁西区华康医院,110026

出　　处：《中国现代药物应用》2022年第7期84-86,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究厄贝沙坦氢氯噻嗪对高血压患者血压变异性和左心室肥厚的影响。方法86例高血压患者,根据治疗方法不同分为对照组和观察组,每组43例。对照组患者采用厄贝沙坦治疗,观察组患者采用厄贝沙坦氢氯噻嗪治疗。比较两组患者治疗前后血压变异性指标(24 h平均收缩压、24 h平均舒张压、24 h收缩压变异值、24 h舒张压变异值)及左心室指标[左心室质量(LVM)、左心室质量指数(LVMI)]。结果治疗后,两组患者24 h平均收缩压、24 h平均舒张压、24 h收缩压变异值、24 h舒张压变异值均低于本组治疗前,且观察组患者24 h平均收缩压、24 h平均舒张压、24 h收缩压变异值、24 h舒张压变异值分别为(110.28±6.24)、(70.18±3.24)、(7.89±0.21)、(8.69±1.11)mm Hg(1 mm Hg=0.133 kPa),低于对照组的(123.32±5.71)、(82.94±1.42)、(9.93±0.38)、(9.68±1.47)mm Hg,差异具有统计学意义(P<0.05)。治疗后,两组患者LVM、LVMI均低于本组治疗前,且观察组患者LVM、LVMI分别为(183.69±8.26)g、(108.93±7.28)g/m^(2),低于对照组的(192.37±11.14)g、(113.85±8.59)g/m^(2),差异具有统计学意义(P<0.05)。结论厄贝沙坦氢氯噻嗪治疗高血压患者能够有效控制血压,降低血压变异性,改善左心室肥厚情况,值得临床推广应用。Objective To investigate the effects of irbesartan and hydrochlorothiazide on blood pressure variability and left ventricular hypertrophy in patients with hypertension.Methods A total of 86 patients with hypertension were divided into control group and observation group according to different treatment methods,with 43 cases in each group.Patients in the control group were treated with irbesartan,and patients in the observation group were treated with irbesartan and hydrochlorothiazide.Both groups were compared in terms of blood pressure variability indexes(24-h systolic blood pressure,24-h diastolic blood pressure,24-h systolic blood pressure variation,24-h diastolic blood pressure variation)and left ventricular indexes[left ventricular mass(LVM),left ventricular mass index(LVMI)].Results After treatment,the 24-h systolic blood pressure,24-h diastolic blood pressure,24-h systolic blood pressure variation,and 24-h diastolic blood pressure variation of the two groups were lower than those of this group before treatment;and the 24-h systolic blood pressure,24-h diastolic blood pressure,24-h systolic blood pressure variation,and 24-h diastolic blood pressure variation of the observation group were(110.28±6.24),(70.18±3.24),(7.89±0.21),and(8.69±1.11)mm Hg(1 mm Hg=0.133 kPa),which were lower than(123.32±5.71),(82.94±1.42),(9.93±0.38),and(9.68±1.47)mm Hg of the control group;all the differences were statistically significant(P<0.05).After treatment,the LVM and LVMI of the two groups were lower than those of this group before treatment,and the LVM and LVMI of the observation group were(183.69±8.26)g and(108.93±7.28)g/m^(2),which were lower than(192.37±11.14)g and(113.85±8.59)g/m^(2) of the control group;all the differences were statistically significant(P<0.05).Conclusion Irbesartan and hydrochlorothiazide for patients with hypertension can effectively control blood pressure,reduce blood pressure variability and improve ventricular hypertrophy,and is worthy of clinical promotion and application.

关 键 词：厄贝沙坦氢氯噻嗪 高血压 血压变异性 左心室肥厚 影响 

分 类 号：R544.1[医药卫生—心血管疾病]